




Figure S1. Flow gating strategy for rat brain immune cells




Figure S2. Flow gating strategy for rat PBMC myeloid cells




Figure S3. Flow gating strategy for rat lymphocytes and elevation of peripheral Tregs in SMM-189-treated rats (high cohort) after 7 weeks of treatment




Figure S4. Targeting of rAAV2/5-hwtAsyn in the rat substantia nigra




Figure S5. Animal body weights and levels of SMM-189 in plasma and CSF






Figure S6. Protein markers for astrocytes, microglia or dopaminergic neurons in striatum do not change by CB2 modulation with SMM-189




Figure S7. Immune cell populations in deep-cervical lymph nodes (DCLN) and splenocytes are minimally affected in SMM-189-treated rats (high cohort) after 7 weeks of dosing